A method for fabricating electrodes sized and dimensioned to record, measure, and/or stimulate very fine nerve structures (e.g., microscale or less) is described herein. The method can include securing a tip of an electrode, comprising a conductor substantially encased by an insulator, to a proximal portion of an inserter. The electrode can be wound around a proximal portion of the inserter and a portion of the electrode can be secured to a distal portion of the inserter. A tension in the electrode can be maintained during the winding to keep the electrode in place during the winding.

A system and computer-implemented method is provided for uncovering genetic drivers of disease in neurodegeneration and other central nervous system (CNS) diseases for novel therapeutic target identification. The process can start with a first integrated, quantitative “deep” imaging phenotype, that accurately reflects disease at a given time-point (cross-sectionally) and returns candidate single nucleotide polymorphisms (SNPs) and/or genes. The candidate SNPs/genes are further validated, by using a second machine learning and/or artificial intelligence (AD-based image analysis operation to assess clinical response, and may include gene expression profiling, and target plausibility analysis including pathway mapping. A set of candidate SNPs/genes may be constructed to accurately predict the first imaging phenotype with a deep learning model from said SNPs/genes to serve as an additional validation step.

A neurostimulation system provides for capture verification and stimulation intensity adjustment to ensure effectiveness of vagus nerve stimulation in modulating one or more target functions in a patient. In various embodiments, stimulation is applied to the vagus nerve, and evoked responses are detected to verify that the stimulation captures the vagus nerve and to adjust one or more stimulation parameters that control the stimulation intensity.

Methods and systems useful for detecting neurological disorders and for measuring general cognitive performance, in particular by measuring eye movements and/or pupil diameter during eye-movement tasks.

Systems and methods evaluate eye movements in Multiple Sclerosis (MS) patients who receive different drugs (e.g., Dimethyl fumarate, Fingolimod, Cladribine, Ofatumumab) or treatments that (a) decrease inflammation and prevent nerve damage that can cause symptoms of multiple sclerosis); (b) test Sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in the lymphocytes nodes, preventing them from contributing to an autoimmune reaction); (c) check an Immune suppressor agent that works on the lymphocyte's pathway) and (d) analyze the effect of Monoclonal Antibodies for inhibiting the activation of lymphocyte B.

Embodiments relate to an object comprising a mask comprising a first portion to cover an eye of a person, the first portion comprising: a first layer and a second layer adjacent to the first layer; an eye pocket; an attachable device; and a bio-monitoring system; wherein the first layer and the second layer form a pouch; and wherein the bio-monitoring system monitors a physiological state of the person, a method of providing a therapy to a person using the object and a method for estimating an effect of the therapy through movement of eyes using the object.

A method for autonomous segmentation of three-dimensional nervous system structures from raw medical images, the method including: receiving a 3D scan volume with a set of medical scan images of a region of the anatomy; autonomously processing the set of medical scan images to perform segmentation of a bony structure of the anatomy to obtain bony structure segmentation data; autonomously processing a subsection of the 3D scan volume as a 3D region of interest by combining the raw medical scan images and the bony structure segmentation data, wherein the 3D ROI contains a subvolume of the bony structure with a portion of surrounding tissues, including the nervous system structure; autonomously processing the ROI to determine the 3D shape, location, and size of the nervous system structures by means of a pre-trained convolutional neural network (CNN).

A typing data analysis system may be used to accurately detect early onset of CNS diseases and psychiatric disorders based on typing data. The typing data analysis system may use distance based data analytics techniques to diagnose CNS diseases and psychiatric disorders with high accuracy. The distance based data analytics techniques may include a distance analysis that determines the distance between two or more sets of inconsistency measures that are associated with a particular individual, disease, or disorder. The distance between inconsistency measures for two or more diseases/disorders may be used to better differentiate between each disease/disorder. The distance between the inconsistency measures for an individual and a disease/disorder may help more accurately screen the individual for the disease/disorder.

Currently, assessing the severity and progression of symptoms in a subject diagnosed with a muscular disability, in particular SMA involves in-clinic monitoring and testing of the subject every 6 to 12 months. However, monitoring and testing a subject more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the subject. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the subject outside of a clinic environment as described herein provides advantages in cost, ease of monitoring and convenience to the subject. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing of the distal motor function of a subject having a muscular disability, in particular SMA by active testing of the subj ect.

A multi-wavelength surgical system is provided using an endoscope sensitive in the short-wave infrared region which allows exploration of different areas of the skull base for CSF leaks. The device includes an LED box with multiple wavelengths including allowing excitation of ICG with 785-808 nm, enhancing the water absorption from 1200-1550 nm and above 1800 nm and incorporating white light to allow for surgical navigation. Because CSF is 99% water having a large absorption in the SWIR band around 1200-1550 nm and above 1800 nm, the system and method should be an effective means of diagnosis without the need for intrathecal fluorescein.